Combined treatment strategies in gastrointestinal stromal tumors (GISTs) after imatinib and sunitinib therapy

Cancer Treatment Reviews

Volumn 36, Issue 1, 2010, Pages 63-68

  Pantaleo, Maria Abbondanza ^a,b   Nannini, Margherita ^a   Di Battista, Monica ^a   Catena, Fausto ^a   Biasco, Guido ^a,b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Gastrointestinal stromal tumors (GISTs); Imatinib; KIT; PGFRA; Sunitinib; Surgery; Tyrosine kinase inhibitors

Indexed keywords

BEVACIZUMAB; EVEROLIMUS; IMATINIB; MIDOSTAURIN; NILOTINIB; PERIFOSINE; RAPAMYCIN; SORAFENIB; SUNITINIB;

ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURGERY; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HETEROZYGOSITY; HUMAN; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL RATE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; GASTROINTESTINAL STROMAL TUMORS; HUMANS; INDOLES; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES;

EID: 74649087010     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2009.10.004     Document Type: Review

References (57)

1. Demetri G.D., von Mehren M., Blanke C.D., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347 (2002) 472-480
2. Demetri G.D., van Oosterom A.T., Garrett C.R., et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib a randomised controlled trial. Lancet 368 (2006) 1329-1338
3. Reichardt P. Novel approaches to imatinib- and sunitinib-resistant GIST. Curr Oncol Rep 10 (2008) 344-349
4. Weisberg E., Manley P.W., Breitenstein W., et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7 (2005) 129-141
5. Montemurro M., Schöffski P., Reichardt P., et al. Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib. Eur J Cancer (2009) [Epub ahead of print]
6. Wiebe L., Kasza K.E., Maki R.G., et al. Activity of sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): a phase II trial of the University of Chicago Phase II Consortium. J Clin Oncol 26 (2008) 20 [suppl; abstr 10502]
7. Reichardt P., Montemurro M., Gelderblom H., et al. Sorafenib fourth-line treatment in imatinib-, sunitinib-, and nilotinib-resistant metastatic GIST: a retrospective analysis. J Clin Oncol 27 (2009) 15s [suppl; abstr 10564]
8. Heinrich M.C., Carden R., Griffith D., et al. In vitro activity of sorafenib against imatinib- and sunitinib-resistant kinase mutations associated with drug-resistant GI stromal tumors. J Clin Oncol 27 (2009) 15s [suppl; abstr 10500]
9. Heinrich M.C., Corless C.L., Demetri G.D., et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumors. J Clin Oncol 21 (2003) 4342-4349
10. Debiec-Rychter M., Dumez H., Judson I., Wasag B., et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 40 (2004) 689-695
11. Heinrich M.C., Owzar K., Corless C.L., Hollis D., Borden E.C., Fletcher C.D., Ryan C.W., von Mehren M., Blanke C.D., Rankin C., Benjamin R.S., Bramwell V.H., Demetri G.D., Bertagnolli M.M., and Fletcher J.A. Correlation of kinase genotype and clinical outcome in the North AmericanIntergroup Phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 26 33 (2008) 5360-5367
12. Desai J., Shankar S., Heinrich M.C., et al. Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors. Clin Cancer Res 13 (2007) 5398-5405
13. Heinrich M.C., Corless C.L., Duensing A., et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299 (2003) 708-710
14. Corless C.L., Schroeder A., Griffith D., et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 23 (2005) 5357-5364
15. Heinrich M.C., Corless C.L., Blanke C.D., et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 24 (2006) 4764-4774
16. Maleddu A., Pantaleo M.A., Nannini M., et al. Mechanisms of secondary resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumours (Review). Oncol Rep 21 (2009) 1359-1366
17. Liegl B., Kepten I., Le C., et al. Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J Pathol 216 (2008) 64-74
18. Wardelmann E., Merkelbach-Bruse S., Pauls K., et al. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res 12 (2006) 1743-1749
19. Bauer S., Duensing A., Demetri G.D., and Fletcher J.A. KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway. Oncogene 26 (2007) 7560-7568
20. Agaimy A., Terracciano L.M., Dirnhofer S., et al. V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours. J Clin Pathol 62 (2009) 613-616
21. Agaram N.P., Laquaglia M.P., Ustun B., et al. Molecular characterization of pediatric gastrointestinal stromal tumors. Clin Cancer Res 14 (2008) 3204-3215
22. Braconi C., Bracci R., Bearzi I., et al. Insulin-like growth factor 1 and 2 help to predict disease outcome in GIST patients. Ann Oncol 19 (2008) 1293-1298
23. Tarn C., Rink L., Merkel E., et al. Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Proc Natl Acad Sci USA 105 (2008) 8387-8392
24. Pantaleo M.A., Astolfi A., Di Battista M., et al. Insuline-like growth factor 1 receptor (IGF1r) expression in wild-type GISTs: a potential novel therapeutic target. Int J Cancer 125 (2009) 2991-2994
25. Yang J., Du X., Lazar A.J., et al. Genetic aberrations of gastrointestinal stromal tumors. Cancer 113 (2008) 1532-1543
26. Gunawan B., von Heydebreck A., Sander B., et al. An oncogenetic tree model in gastrointestinal stromal tumours (GISTs) identifies different pathways of cytogenetic evolution with prognostic implications. J Pathol 211 (2007) 463-470
27. Weisberg E., Wright R.D., Jiang J., et al. Effects of PKC412, Nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity. Gastroenterology 131 (2006) 1734-1742
28. Reichardt P., Casali P.G., Blay J., et al. A phase I study of AMN107 alone and in combination with imatinib in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (GIST). J Clin Oncol (2006) 9545
29. Blay J.Y., Casali P.G., Reichardt P., et al. A phase I study of nilotinib alone and in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors (GIST): Study update. J Clin Oncol 26 (2008) [May 20 suppl; abstr 10553]
30. Van Oosterom A.T., Dumez H., Desai J., et al. Combination signal transduction inhibition: A phase I/II trial of the oral mTOR-inhibitor everolimus (E, RAD001) and imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM. J Clin Oncol (2004) 3002
31. Dumez H., Reichard P., Blay J.Y., et al. A phase I-II study of everolimus (RAD001) in combination with imatinib in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (GIST). J Clin Oncol 26 (2008) [May 20 suppl; abstr 10519]
32. Palassini E., Fumagalli E., Coco P., et al. Combination of PKC412 and sirolimus in a metastatic patient with PDGFRA-D842V gastrointestinal stromal tumor (GIST). J Clin Oncol 26 (2008) [May 20 suppl; abstr 21515]
33. Piovesan C., Fumagalli E., Coco P., et al. Response to sirolimus in combination to tirosine kinase inhibitors (TKI) in three cases of PDGFRA-D842V metastatic gastrointestinal stromal tumor (GIST). J Clin Oncol 27 (2009) 15s [suppl; abstr 10565]
34. Conley P., Araujo D., Ludwig J., et al. A randomized phase II study of perifosine (P) plus imatinib for patients with imatinib-resistant gastrointestinal stromal tumor (GIST). J Clin Oncol 27 (2009) 15s [suppl; abstr 10563]
35. Schoffski P., Floris G., Sciot R., et al. Assessment of the heat shock protein 90 (HSP90) inhibitor IPI504 alone or in combination with the tyrosine kinase inhibitor (TKI) imatinib in mice carrying xenografts of human gastrointestinal stromal tumors (GIST). J Clin Oncol 27 (2009) 15s [suppl; abstr 10534]
36. Fabbro D., Ruetz S., Bodis S., et al. PKC412 - a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des 15 (2000) 17-28
37. Prenen H., Guetens G., de Boeck G., et al. Cellular uptake of the tyrosine kinase inhibitors imatinib and AMN107 in gastrointestinal stromal tumor cell lines. Pharmacology 77 (2006) 11-16
38. Wang L., Giannoudis A., Lane S., Williamson P., Pirmohamed M., and Clark R.E. Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther 83 (2008) 258-264
39. Bonvalot S., Eldweny H., Pechoux C.L., et al. Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era. Ann Surg Oncol 13 (2006) 1596-1603
40. Andtbacka R.H., Ng C.S., Scaife C.L., et al. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol 14 (2007) 14-24
41. Raut C.P., Posner M., Desai J., et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 24 (2006) 2325-2331
42. Gronchi A., Fiore M., Miselli F., et al. Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST. Ann Surg 245 (2007) 341-346
43. DeMatteo R.P., Maki R.G., Singer S., Gonene M., Brennan M.F., and Antonescu C.R. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg 245 (2007) 347-352
44. Scaife C.L., Hunt K.K., Patel S.R., et al. Is there a role for surgery in patients with unrespectable cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate?. Am J Surg 186 (2003) 665-669
45. Wu P.C., Langerman A., Ryan C.W., Hart J., Swiger S., and Posner M.C. Surgical treatment of gastrointestinal stromal tumors in the imatinib era. Surgery 134 (2003) 665-666
46. Rutkowski P., Nowecki Z., Nyckowski P., et al. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate. J Surg Oncol 93 (2006) 304-311
47. Haller F., Dekten S., Schulten H.-J., et al. Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumors (GIST) with respect to imatinib resistance caused by secondary KIT mutations. Ann Surg Oncol 14 (2007) 526-532
48. Fiore M., Palassini E., Fumagalli E., et al. Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST). Eur J Surg Oncol 35 (2009) 739-745
49. Katz D., Segal A., Alberton Y., et al. Neoadjuvant imatinib for unresectable gastrointestinal stromal tumor. Anticancer Drugs 15 (2004) 599-602
50. Al-Batran S.E., Hartmann J.T., Heidel F., et al. Focal progression in patients with gastrointestinal stromal tumors after initial response to imatinib mesylate: a three-center-based study of 38 patients. Gastric Cancer 10 (2007) 145-152
51. Hasegawa J., Kanda T., Hirota S., et al. Surgical interventions for focal progression of advanced gastrointestinal stromal tumors during imatinib therapy. Int J Clin Oncol 12 (2007) 212-217
52. Bauer S., Hartmann J.T., de Wit M., et al. Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib. Int J Cancer 117 (2005) 316-325
53. Pantaleo M.A., Di Battista M., Catena F., et al. Surgical debulking of gastrointestinal stromal tumors: is it a reasonable option after second-line treatment with sunitinib?. J Cancer Res Clin Oncol 134 (2008) 625-630
54. Choi W.H., Kim S., Hyung W.J., et al. Long-surviving patients with recurrent GIST after receiving cytoreductive surgery with imatinib therapy. Yonsei Med J 50 (2009) 437-440
55. Pantaleo M.A., Landuzzi L., Nicoletti G., et al. Advances in preclinical therapeutics development using small animal imaging and molecular analyses: the gastrointestinal stromal tumors model. Clin Exp Med 9 (2009) 199-205
56. Pantaleo M.A., Nannini M., Maleddu A., et al. Conventional and novel PET tracers for imaging in oncology in the era of molecular therapy. Cancer Treat 34 (2008) 103-121
57. Kil K.E., Ding Y.S., Lin K.S., et al. Synthesis and positron emission tomography studies of carbon-11-labeled imatinib (Gleevec). Nucl Med Biol 34 (2007) 153-163